VANCOUVER, British Columbia, Dec. 14, 2023 (GLOBE NEWSWIRE) -- MedBright AI Investments Inc. (the “Company” or “MedBright”) (CSE:MBAI, OTCQB:MBAIF, FSE:1V7) today announced that CareMEDICA, a leading clinic group and provider of primary care services in Connecticut and South Florida has chosen to implement the beta version of MedMatrix into its practice. CareMEDICA has long-standing affiliations with Yale University School of Medicine and Quinnipiac University Medical Program.
MedMatrix, an AI-powered data analytics platform, harnesses the power of artificial intelligence to evaluate and analyze key aspects of healthcare facilities, including patient needs and resource matching, revenue cycle management, patient demographics, facility geography, and competition. Through its advanced AI and data analytics capabilities, MedMatrix works alongside healthcare professionals to optimize each of these critical areas, resulting in more efficient clinic operations and improved patient outcomes.
Established over 20 years ago, CareMEDICA is a leading provider of primary care services for patients throughout Connecticut and the South Florida region. Their providers share the belief in a more personal approach to healthcare, where patients are fully seen, heard, and catered to in ways that far surpass the limitations of standard primary care. CareMEDICA’s clinical roster is comprised of some of the most talented and dedicated medical professionals in the nation, constantly pushing the boundaries of what is possible in the world of modern medicine. “It makes natural sense to leverage AI as a tool to help improve clinical efficiency, as it can process data much faster than the human mind,” said Fausto Petruzziello, MD, Medical Director of CareMEDICA. “I’m looking forward to seeing the positive outcomes that MedMatrix can provide.”
“We are thrilled to have CareMEDICA, Dr. Petruzziello, and his team of highly talented medical professionals as beta customers of the MedMatrix Platform,” said Michael Dalsin, Chairman of Healthcare Accretion AI’s investment committee. “We look forward to launching the product at CareMEDICA’s Connecticut facilities and highlighting the positive outcomes that can be made working with the CareMEDICA team.”
This new beta customer comes in addition to last weeks announcement where MedBright announced the first beta customer for MedMatrix.
MedBright AI is a capital allocator focused on investing in healthcare technology companies. The team at MedBright prides themselves on unparalleled access to opportunities, as well as structuring unique and advantageous investments. MedBright's mission is to construct a portfolio of synergistic investments to generate superior returns for shareholders. MedBright will focus on significant near-term and midterm high-quality opportunities with strong return potentials while maintaining commitment to governance.
MedBright AI Investments Inc.
Alnoor Nathoo, Chief Executive Officer
Cautionary Statement Regarding "Forward-Looking" Information
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including, without limitation, the anticipated benefits of MedMatrix such as increased clinic revenue, enhanced patient satisfaction, reduced wait times and physician burnout, including with respect to its use by CareMEDICA, and the Company’s plans to generate returns for its shareholders through its portfolio of investments, are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should” or “would” or occur.
Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including, among other things, that MedMatrix will offer increased clinic revenue, enhanced patient satisfaction, reduced wait times and physician burnout, and that the Company will be able to generate returns for its shareholders. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important risks that may cause actual results to vary, include, without limitation, the risk that the use of MedMatrix will not result in increased clinic revenue, enhanced patient satisfaction, or reduced wait times and physician burnout, and the risk that the Company’s portfolio of investments will not generate returns for shareholders.
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.